Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
| 0.025 | |
| 0.026 | |
| - | |
| 0.026 | |
| 0.024 | |
| 0.016-0.066 | |
| 3 073 K | |
| 121 M | |
| 827 K | |
| -0.0067 | |
| 1.097 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease in Phase 3 study ATI-1801 may be eligible for tropical disease priority review vouch...
Virtual Investor Conferences NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
